Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Helix BioPharma Corp.TSX: HBP.TO
Cash & Equivalents · Q3 FY2026 · quarter ended Apr 2026
Cash & equivalents rises 297.5% from a year ago
Cash & equivalents stood at CA$2.84M at the end of Q3 FY2026, up 297.5% from a year earlier and up 9067.7% from the prior quarter. Over 3 fiscal years it compounded at -72.9% a year.
Context
- Cash & equivalents amounted to 13.3% of total assets at the end of Q3 FY2026, down 57.6 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +297.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
CAD · from the balance sheet
- Latest · FY2025
- 65K CAD
- Year-over-year change
- -94.0%
- 4-year CAGR
- -63.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 65K | -94.0% |
| FY2024 | 2024-07-31 | 1.08M | +33.8% |
| FY2023 | 2023-07-31 | 808K | -75.2% |
| FY2022 | 2022-07-31 | 3.25M | -8.8% |
| FY2021 | 2021-07-31 | 3.57M | — |
Cash & Equivalents vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +297.5% is the highest of 5, against a peer median of -36.9%.
- Cash & equivalents amounts to 13.3% of total assets for HBP.TO, versus a peer median of 46.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$27.67M CAD | +18.8% | -28.9% | 88.1% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $18.71M USD | -43.4% | +72.0% | 24.9% |
| Mar 2026 | $12.33M USD | -30.4% | -17.3% | 9.4% | |
| Apr 2026 | CA$2.84M CAD | +297.5% | -72.9% | 13.3% | |
| Apr 2026 | CA$1.05M CAD | -47.3% | -58.8% | 68.6% | |
| Peer median (excluding HBP.TO) | — | -36.9% | -23.1% | 46.8% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.